Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...

Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY ...

The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...

Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV). The 3-part, randomized, ...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., March 03, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

Polycythemia Vera is a rare disorder marked by a continuous rise in the number of red blood cells in the blood, with an ...

An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...

Protagonist Therapeutics (NASDAQ:PTGX) and Takeda (NYSE:TAK) said on Monday that its late-stage study of rusfertide for the ...

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) today announced positive ...